Actively Recruiting
Study of the Fully Closed Loop Omnipod M System for Safety and Effectiveness in Adults with Type 2 Diabetes Using Insulin Therapy
Led by Insulet Corporation · Updated on 2026-08-03
350
Participants Needed
27
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of the fully closed loop Omnipod M System in adults with type 2 diabetes who use basalbolus or basal-only insulin therapy. This multi-center randomized controlled trial lasts 26 weeks, with key results measured after 15 and 26 weeks. After this period, an extension phase allows the control group to switch to the Omnipod M system while the intervention group continues its use. Participants are divided into two groups one uses the Omnipod M system with a study continuous glucose monitor CGM, while the other continues their usual insulin regimen with the study CGM. The extension phase lasts an additional 26 weeks, during which the control group crosses over to use the Omnipod M system. The study includes regular monitoring of glucose levels and insulin use throughout. During the trial, participants will wear the study CGM and either the Omnipod M system or their standard insulin treatment. Researchers will assess blood sugar control through measures like HbA1c and time spent in target glucose ranges at 15 and 26 weeks. Additional evaluations include glucose variability and diabetes-related distress. Participants are expected to use study devices continuously and attend scheduled visits over the trial and extension periods, with safety and adherence closely monitored.
CONDITIONS
Brief Title
Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes
Research Team
T
Trang Ly, MBBS, PhD
B
Bonnie Dumais, RN
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here